Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).
Julie E. Bauman
Research Funding - Bristol-Myers Squibb; Genentech; Lilly
William E. Gooding
No relevant relationships to disclose
David Andrew Clump
No relevant relationships to disclose
Seungwon Kim
No relevant relationships to disclose
Brian J Karlovits
No relevant relationships to disclose
Dwight Earl Heron
No relevant relationships to disclose
Umamaheswar Duvvuri
Honoraria - Novartis
James Ohr
No relevant relationships to disclose
Karen Holeva
No relevant relationships to disclose
Robert L. Ferris
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb
Research Funding - Amgen; Bristol-Myers Squibb